Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Bone Marrow Transplantation
|
June 20, 2018
Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy
C Amos Clark, Claudio A Mosse, Heidi Chen, et al.
Bone Marrow Transplantation
|
January 30, 2020
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
Dilan A Patel, Ragisha Gopalakrishnan, Brian G Engelhardt, et al.
Leukemia Research
|
January 9, 2018
Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia
Stephen A Strickland, Aaron C Shaver, Michael Byrne, et al.
The American Journal of Pathology
|
August 8, 2021
miR-378-3p Knockdown Recapitulates Many of the Features of Myelodysplastic Syndromes
Dahai Wang, Miao Lin, Begum Utz, et al.
Archives of Pathology & Laboratory Medicine
|
August 21, 2019
Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431
Kelley J Mast, Jeffrey W Taub, Todd A Alonzo, et al.
American Journal of Clinical Pathology
|
October 15, 2013
Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approach
Adam C Seegmiller, Annette S Kim, Claudio A Mosse, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 13, 2026
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Bone Marrow Transplantation
|
June 20, 2018
Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy
C Amos Clark, Claudio A Mosse, Heidi Chen, et al.
Bone Marrow Transplantation
|
January 30, 2020
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
Dilan A Patel, Ragisha Gopalakrishnan, Brian G Engelhardt, et al.
Leukemia Research
|
January 9, 2018
Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia
Stephen A Strickland, Aaron C Shaver, Michael Byrne, et al.
The American Journal of Pathology
|
August 8, 2021
miR-378-3p Knockdown Recapitulates Many of the Features of Myelodysplastic Syndromes
Dahai Wang, Miao Lin, Begum Utz, et al.
Archives of Pathology & Laboratory Medicine
|
August 21, 2019
Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431
Kelley J Mast, Jeffrey W Taub, Todd A Alonzo, et al.
American Journal of Clinical Pathology
|
October 15, 2013
Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approach
Adam C Seegmiller, Annette S Kim, Claudio A Mosse, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 13, 2026
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Page
of 3